The increased intestinal permeability relates to the potency of the drug to inhibit cyclooxygenase and, as is evident from studies of fractional urine collections, damage occurs throughout the intestine rather than being localised to the proximal small intestine. This has been shown, for example, for indomethacin administered as a suppository.' The situation is more complex however, because the effect of most NSAIDs on the gut can be envisaged as a summation of three events.99 Initially, during drug absorption there is a high local concentration of NSAID in the proximal small bowel where it exerts its full metabolic effects. After absorption the drug is distributed widely and diluted so that the systemic effect is only a fraction of what occurs locally during absorption. Third, most NSAIDs are secreted in bile to a significant extent which may further expose the small intestine to the drug. Consideration of the above and the fact that NSAIDs frequently cause inflammation of the small intestine in the experimental animal and humans rather than damage to the colon,34 has led us to concentrate our studies on the small intestinal effect (0-5 hour urines) of NSAIDs on intestinal permeability.
If, as suggested, NSAIDs damage the intestine by inhibiting cyclooxygenase thereby reducing mucosal prostaglandin production and diverting arachidonic acid metabolism into the lipooxygenase pathway, this will lead to increased production of proinflammatory leukotrines. This hypothesis had been assessed indirectly in volunteers by the coadministration of prostaglandins with NSAIDs. Misopostol a stabile prostaglandin El analogue had no effect on Naproxen induced increased intestinal permeability when given independently."'When given at relatively high doses half an hour before indomethacin, however, misoprostol had a significant protective effect.99 Moreover a small dose of rioprostol given at the same time as indomethacin has a maximal protective action 7 suggesting that it is the initial damage during absorption of the NSAID that is the most important of the three phases in increasing small intestinal permeability. As we believe that it is this initial and immediate effect of NSAID to increase small intestinal permeability which is the prerequisite for the subsequent development of small intestinal inflammation by exposing the mucosa to luminal substances and perhaps, as in the experimental animal, paving the way for a bacterial invasion, further studies should concentrate on the means by which NSAID-induced increased intestinal permeability can be prevented.
There are a number of ways of examining the mechanism by which NSAIDs increase intestinal permeability. Most NSAIDs have a carboxylic acid residue which, by virtue of a low pk, may be locally irritating: Non-steroidal anti-inflammatory drugs may increase lysosomal fragility by the generation of oxygen derived free radicals, potentiated by vasoconstriction. Thus the simultaneous administration of free radical scavengers may be beneficial. It is suggested that NSAIDs damage the small intestine of the experimental animal by inhibiting steps in the anaerobic glycolytic pathway and the tricarboxylic acid cycle. This results in a reduced synthesis of ATP thereby impairing the survival of the injured cell. 99 The administration of glucose and citrate, the metabolic precursors for glycolysis and the TCA cycle respectively, protect against damage medicated by indomethacin in the experimental animal.9A Preliminary results suggest a similar reduction in the indomethacin induced effects on intestinal permeability in man. Agents that selectively inhibit lipooxygenase and thromboxane synthase (dazmegril) could provide a means of exploring the mechanisms of NSAID toxicity to the small intestine. Finally the effects of pro-NSAIDs would be of particular interest in distinguishing between the importance of local versus systemic toxicity since these drugs are only activated in the liver after absorption and, at least with nabumatone (Relifex), there is no biliary excretion of the active drug.
Whatever the final mechanism underlying the increased intestinal permeability due to NSAIDS, the objectives of the above studies are two-fold. First, they could establish, in longterm studies, the pathogenic importance of altered intestinal permeability and, second, they offer the prospect of reducing the frequency and severity of the associated complication of NSAID enteropathy. 
NSAID enteropathy
Because permeability changes with NSAIDs are quantitatively similar to those found in inflammatory bowel disease, evidence of intestinal inflammation was specifically sought with "'Indium labelled leucocytes.2 2331 3' The technique has been extensively validated for the localisation of occult infections and segmental involvement in inflammatory bowel disease. There is a good correlation between scintigraphic and radiological location of inflammatory bowel disease and between "'Indium faecal excretion and clinical correlates for quantitation of disease activity. Depending on whether intestinal inflammation was judged by abdominal scintigrams or by the four day faecal excretion of "'Indium, 45% and 70%, respectively, of patients on longterm NSAIDs have evidence of intestinal inflammation."3 The inflammation is only consistently evident after more than six months of NSAID ingestion. No 29 patients on NSAIDs quantifying both the faecal "I'In activity and the 5'Chromium red cell intestinal blood loss a significant correlation was found between the two (r:0-59, p<0-01), further supporting the idea that NSAID enteropathy is associated with intestinal bleeding.
The clinical importance of a chronic daily blood loss of 1-8 ml depends on a variety of factors, but essentially revolves around iron homeostasis. Iron homeostasis is assured by an adequate intake of a nutritious diet, the availability of iron for absorption, the regulation of the intestinal iron transport and, of course, the basal iron loss. In the context of patients with rheumatoid athritis it is clear that many of the above factors may be impaired so as to render them borderline iron deficient. Thus cachexia associated with active disease as well as dyspepsia duc to NSA I Ds mayx limit food intake. Hypochlorlhydria as a resuilt of antacids, pernicious anaemiia or chroniic gastritis mllaV reducc the availlability of iron for absorption. The activity of the intestinal iron transport system is impaired in relation to their iron stores. It is unider these circumstances that mild chronic blood loss from the gut has its greatest clinical impact in depletilng existing iron stores and renderinig the patielnts iron deficient. The precisc definition of an iroi deficient anaemia in the rheumatoid patient is, however. difficult as it is ofteii superimposed oii the anaemia of chronic disease which is of course associated with an erythroid precursor defcct in assimilating available marrow iron. Nevertheless miany rhliumatologists empirically treat patients with haemoglobin levels below 10 g/dl with iron, with improvement, but not normalisation of haemoglobin levels.
Protein loss
Nine patients on NSAIDs underwent a simultaneous study with "'In leucocytes and a study of intestinal protein loss using 51CrCl3. All six patients with NSAID enteropathy had a protein losing enteropathy but the number of patients was too small to assess reliably whether there was a significant correlation between the two variables. The importance of chronic protein loss has to be viewed in the context of whole body protein turnover, but may explain the hypoalbuminaemia of some patients with rheumatoid arthritis. Considering the number of patients on long term treatment with NSAIDs this may be one of the most frequent causes of a protein losing enteropathy world wide.
Ileal dysfunction
Ileal function was assessed by whole body retention of orally administered [7" Se] labelled-25-homocholic acid (75SeHCAT) and "xCo labelled cyanobalamin ("'Co vitB 12). The purpose of the study was not only to assess ileal function in 20 patients on NSAIDs but also to compare the sensitivity of the two markers in 13 patients with ileal Crohn's disease. 23 The results showed that 13 of 20 patients on NSAIDs had 75Se HCAT malabsorption of whom four only had borderline reduced absorption of 8Co vitB 12. In the Crohn's patients 75Se HCAT was found to be a much more sensitive indicator of ileal function than 58Co vitB12. Furthermore "xCo vitB12 was such a poor indicator of ileal function as to render the test quite useless for screening purposes (Fig. 1) 
Treatment of NSAID enteropathy
Therapy is often based on the understanding of the disease process but more often it is empirical. As, NSAID enteropathy has so many similarities with Crohn's disease of the small intestine, however, we have attempted treatment with sulphasalazine. As patients with active agressive rheumatoid arthritis benefit from sulphasalazine the initial study involved only patients requiring a second line agent. Forty patients were studied before and after sulphasalazine and 20 before and after other second line drugs -for example, gold, penicillamine, chloroquine, while maintaining an unchanged NSAID intake. Sulphasalazine reduced significantly the faecal "'In excretion while the other second line drugs did not (data submitted). Both groups of patients benefitted similary with regard to reduced joint inflammation. There was, however, no significant correlation between the beneficial response of sulphasalazine on the joints and the intestine suggesting the NSAID enteropathy does not have a detrimental effect on the joints as previously suggested. Preliminary studies assessing intestinal blood loss, as well as inflammation, before and after sulphasalazine suggest that reduced intestinal inflammation is matched by reduced intestinal blood loss.
The implication of these studies will depend on our perception of the problem. In mild cases of rheumatoid arthritis where the patient needs only simple and infrequent analgesics nothing needs to be done. In contrast the badly controlled patients who frequently develop iron deficiency without 'apparent' cause needs careful consideration. Clearly sulphasalazine might be a suitable first choice of drug under these circumstances, especially as iron supplements are so badly tolerated by many of these patients. The 
